Back HIV/AIDS

HIV / AIDS

AIDS 2016: Earlier HIV Treatment Is Not Over-burdening Health Services

Earlier antiretroviral treatment initiation is not overwhelming rural health services in South Africa, but changes in treatment eligibility criteria alone may not be enough to increase the number of people on treatment substantially, and more investment will be needed in testing and linkage to care to reach treatment coverage goals, research presented at the recent 21st International AIDS Conference (AIDS 2016) shows.

alt

San Francisco Annual Report Shows New Low in HIV Infections But Disparities Remain

On September 1, the San Francisco Department of Public Health released its HIV Epidemiology Annual Report 2015, showing that the number of newly diagnosed HIV infections has continued to fall and people with HIV are being linked to care and achieving viral suppression more quickly. But some notable disparities remain, with African-American men and women not benefitting as much as the population as a whole.

alt

AIDS 2016: Study Looks at Use of HIV PrEP Before and During Pregnancy and Breastfeeding

Truvada for pre-exposure prophylaxis (PrEP) when it was offered as an additional tool for preventing HIV infection during the pre-conception period, pregnancy, and breastfeeding, according to study findings presented at the 21st International AIDS Conference (AIDS 2016) last month in Durban and published in the July 19 online edition of the American Journal of Obstetrics and Gynecology.

alt

AIDS 2016: Managing Non-Communicable Diseases Among People Living with HIV

Speakers at the recent 21st International AIDS Conference in Durban addressed non-communicable diseases (NCDs) -- including cardiovascular diseases, diabetes, cancers, and other illnesses -- which have become more common complications for people with HIV who are living longer on antiretroviral therapy (ART). NCDs represent a significant challenge in low- and middle-income countries, where the burden of these illnesses has been reaching epidemic proportions, but where health systems have traditionally focused on providing episodic rather than chronic care.

alt

Truvada PrEP for HIV Prevention Approved in European Union

The European Commission, which has authority over new drug in the European Union, has approved Truvada (tenofovir/emtricitabine) for HIV pre-exposure prophylaxis or PrEP, Gilead Sciences announced this week. While this marketing authorization allows Truvada for PrEP to be sold throughout the EU, regulatory authorities in each country have the final say over whether to approve it and national health systems will decide whether to offer PrEP widely and pay for it.

alt

AIDS 2016: San Francisco Sees Progress in Getting to Zero Initiative

San Francisco continues to make good progress with its "Getting to Zero" initiative, which aims to achieve the triple goal of zero new HIV infections, zero AIDS deaths, and zero stigma for people living with HIV. But not all groups are doing equally well, according to a presentation at the recent 21st International AIDS Conference (AIDS 2016) in Durban.

alt

AIDS 2016: New HIV Infections Have Stopped Declining Worldwide, Now Rising in Some Regions

After a decade of rapidly declining HIV incidence following the introduction of effective antiretroviral treatment, progress in reducing new infections has stalled worldwide and in some areas incidence has started to increase, according to a new analysis from the Global Burden of Disease Study presented at the 21st International AIDS Conference (AIDS 2016) last month in Durban and published in the August 2016 edition of The Lancet HIV.

alt